Download or read book Clinical Trials In Parkinson s Disease written by Santiago Perez-Lloret and published by Humana. This book was released on 2020-08-19 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume looks at major clinical trials for motor and non-motor symptoms in Parkinson’s Disease (PD) and covers important aspects, including trial design, sample selection, and outcome selection. Chapters in this book discuss topics such as toxin-based rodent or genetic models of PD; clinical trials for motor symptoms, L-DOPA related motor complications, and gait disorders; clinical trials for mood disorders, troubled sleep, autonomic dysfunction; and clinical trials for disease modifying therapies. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory or research center. Cutting-edge and authoritative, Clinical Trials in Parkinson’s Disease is a valuable resource for clinicians and researchers who want to enhance their interpretation of results from clinical trials and to design their own high-quality trials.
Download or read book Clinical Studies and Therapies in Parkinson s Disease written by Juan Segura-Aguilar and published by Academic Press. This book was released on 2021-06-12 with total page 306 pages. Available in PDF, EPUB and Kindle. Book excerpt: More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson’s disease, but it remains the most common treatment despite inducing severe side effects such as dyskinesia after 4–6 years of use. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies for Parkinson’s disease, but these efforts have failed when attempting to transfer these successful results to preclinical studies. Although several publications have warned of these failures, the scientific community remains mostly unaware, and there is a need to focus their efforts on potential therapeutics that can slow or halt development of the disease. Clinical Studies and Therapies in Parkinson’s Disease: Translations from Preclinical Models analyzes preclinical models based on exogenous neurotoxins and why they have failed. Neuroscientists, neurologists, and neuropharmacologists will benefit greatly from the book’s discussion of these newer models, their benefits, and the need for their implementation. This book also provides the basic concepts of dopamine metabolism for students taking courses in neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine. Reviews Parkinson's disease classification, pharmacological therapies, and nonmotor and motor symptoms Analyzes preclinical models of Parkinson’s disease therapies based on exogenous neurotoxins and why they have failed Reviews genetic preclinical models based on genetic mutations and endogenous neurotoxins Proposes a more physiological model directly related to the metabolism of dopaminergic neurons Provides the basic concepts and mechanisms of dopamine metabolism
Download or read book Levodopa pharmacokinetics from stomach to brain written by Maria Nord and published by Linköping University Electronic Press. This book was released on 2019-01-07 with total page 72 pages. Available in PDF, EPUB and Kindle. Book excerpt: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients. In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment. To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery. Parkinsons sjukdom (PS) är en av de vanligaste s.k. neurodegenerativasjukdomarna och orsakas av förlust av dopamin(DA)producerande nervceller i hjärnan. Detta orsakar motoriska symptom såsom skakningar, stelhet och förlångsammade rörelser. Levodopa (LD) är ett ämne, som kan omvandlas till DA i hjärnan och ge symptomlindring och det är oftast förstahandsval vid behandling av patienter med PS. Flera faktorer påverkar tillgängligheten av LD, bl.a. den hastighet som magsäcken tömmer sig med och denna verkar förlångsammad hos personer med PS vilket ger sämre tillgänglighet av LD i blodet och därmed i hjärnan. LD bryts även ner i hög grad av olika enzym ute i kroppen vilket leder till mindre mängd LD som hamnar i hjärnan och till fler nedbrytningsprodukter som orsakar biverkningar. Tillägg av enzymhämmare leder till ökad mängd LD som kan nå hjärnan och omvandlas till DA. Det anses viktigt att undvika höga toppar av LD i hjärnan då dessa verkar bidra till utvecklandet av besvärliga motoriska komplikationer hos patienter med PS. Om LD ges mer kontinuerligt, exempelvis som en kontinuerlig infusion in i tarmen eller i blodet, så minskar dessa motoriska komplikationer. Inopererande av stimulatorer i vissa delar av hjärnan (DBS) har också visat sig minska dessa motoriska komplikationer och även resultera i att man kan minska LD-dosen. Huvudsyftet med den här avhandlingen är att studera LD hos patienter med PS; i blod och fettvävnad då LD ges i tablettform och se om det finns något samband med LD-upptag och hastigheten på magsäckstömningen (MT) och om kontinuerligt given LD påverkar LD-upptaget eller MT; i blod och i ryggmärgsvätska då enzymhämmarna entakapon och karbidopa tillsätts LD; i hjärna vid behandling med DBS och då LD ges både som tablett och som infusion i blodet. Sammanfattningsvis kan vi se att LD-upptaget är mer gynnsamt hos patienter med PS i tidigare skede av sjukdomens komplikationsfas. MT är förlångsammad hos patienter med PS och det är inget tydligt samband mellan LD-upptag och MT eller mellan MT och sjukdomsgrad. Kontinuerligt given LD minskar LDnivåerna. Enzymhämmaren entakapon ökar den maximala koncentrationen av LD i blod och ryggmärgsvätska och effekten är mer tydlig vid tillägg av karbidopa vilket är viktigt att ta i beaktande vid behandling av PS för att undvika höga toppar av LD i hjärnan. LD ökar i hjärnan då man behandlar med LD i tablettform och som infusion i blodet och DA-nivåerna i hjärnan följer LD väl vilket visar på att patienter med PS fortfarande kan omvandla LD till DA trots trolig uttalad brist av de DA-producerande nervcellerna i hjärnan. DBS verkar öka DA i vissa områden i hjärnan och tillsammans med LD-infusion i blodet verkar det även öka LD i hjärnan och det kan förklara varför man kan sänka LDdosen efter DBS-operation.
Download or read book Etiology of Parkinson s Disease written by Jonas H. Ellenberg and published by CRC Press. This book was released on 1995-03-01 with total page 600 pages. Available in PDF, EPUB and Kindle. Book excerpt: This comprehensive reference provides a detailed overview of current concepts regarding the cause of Parkinson's disease-emphasizing the issues involved in the design, implementation, and analysis of epidemiological studies of parkinsonism.
Download or read book The New Parkinson s Disease Treatment Book written by J. Eric Ahlskog, PhD, MD and published by Oxford University Press. This book was released on 2015-08-03 with total page 545 pages. Available in PDF, EPUB and Kindle. Book excerpt: The fundamental guide to the most effective treatments for Parkinson's Disease, from a Mayo Clinic doctor with thirty years of clinical and research experience. In this second edition follow-up to the extremely successful first edition, Dr. Ahlskog draws on thirty years of clinical experience to present the definitive guide to dealing with all aspects of Parkinson's Disease, from treatment options and side effects to the impact of the disease on caregivers and family. Dr. Ahlskog's goal is to educate patients so that they can better team up with their doctors to do battle with the disease, streamlining the decision-making process and enhancing their treatment. To do this, Dr. Ahlskog offers a gold mine of information, distilled from his years of experience treating people with Parkinson's at the Mayo Clinic. In addition to providing a comprehensive account of Parkinson's medications, this book also examines additional aspects of treatment, such as the role of nutrition, exercise, and physical therapy. Although many commendable texts have been written on the subject of Parkinson's Disease, their discussions of treatment have not been in depth. Dr. Ahlskog sifts through aspects of the disease in order to give the reader a comprehensive sense of Parkinson's and the best available treatment options. With a broader understanding of the disease and the available options, patients are able to make more informed choices, and doctors are able to provide more tailored care. This book delivers hopeful, helpful, and extensive information to all parties concerned: patients, caregivers, and doctors. The ultimate guide to symptoms and treatment, this thoroughly updated second edition is the first place patients should turn for reliable, easy-to-grasp information on Parkinson's Disease.
Download or read book Restorative Therapies in Parkinson s Disease written by Patrik Brundin and published by Springer Science & Business Media. This book was released on 2006-08-31 with total page 397 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this exciting and timely book new approaches to repairing the parkinsonian brain are described by leading experts. Never in history has there been greater hope that novel experimental therapies can support significant restoration of brain function. This book gives an overview of the current state-of-the-art research for brain repair, what the challenges are and an indication of what research can provide for the next generation of people with Parkinson’s disease. The comprehensive chapters are geared to an audience of neuroscientists, neurologists, neurosurgeons and anyone interested in how findings in the research laboratory can effectively be transferred to the clinic.
Download or read book Parkinson s Disease Animal Models Current Therapies and Clinical Trials written by Sarat Chandra Yenisetti and published by BoD – Books on Demand. This book was released on 2023-12-20 with total page 252 pages. Available in PDF, EPUB and Kindle. Book excerpt: Despite being described about 200 years ago, the pathophysiology of Parkinson’s disease (PD) is not well understood due to its complex etiology and heterogeneity of symptoms and progression. Animal models provide a great opportunity to follow the progression of neurodegeneration and to screen potent therapeutic molecules, knowledge of which can be critical for different levels of clinical trials. Contemporary health technologies are coming in handy to accelerate the pace of developing novel and refined therapeutic strategies for PD. This book, Parkinson’s Disease - Animal Models, Current Therapies and Clinical Trials, provides a comprehensive overview of PD, presenting information on animal models of PD and contemporary therapeutic strategies, health technologies, clinical trials, and their influence on the quality of life of patients with PD.
Download or read book Recent Advances in Parkinson s Disease written by and published by Elsevier. This book was released on 2020-04-16 with total page 578 pages. Available in PDF, EPUB and Kindle. Book excerpt: Recent Advances in Parkinson ́s Disease Research, Volume 252, represents a follow-up on two previous volumes presented in the Progress in Brain Research series, Volumes 193 and 193, both published in 2010. It contains a collection of overview articles written by leading researchers in Parkinson's, discussing the most important advances made in basic, translational and clinical research. Topics of note in this new release include What can we learn from iPS cell models of PD, What can we learn from animal models of PD?, Molecular basis of selective neuronal vulnerability in PD, Role of innate and adaptive immunity in Parkinson ́s disease, and much more. Covers all key aspects of current research on Parkinson ́s disease Includes topics that range from basic studies on disease models and pathogenic pathways (e.g., protein misfolding, immune and glial mechanisms) to clinical studies on disease features, microbiome, pathophysiology and therapeutic approaches Presents articles authored by world leaders in their respective fields
Download or read book Diagnosis and Treatment of Parkinson s Disease written by Cindy Levine and published by Department of Health and Human Services Pu Ncy for Healthcare Res. This book was released on 2003-01-01 with total page 306 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Parkinson s Disease Current and Future Therapeutics and Clinical Trials written by Néstor Gálvez-Jiménez and published by Cambridge University Press. This book was released on 2016-03-24 with total page 385 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book emphasizes treatment options for Parkinson's disease, providing the necessary clinical and scientific basis for the foundations of solid therapeutics.
Download or read book Parkinson s Disease written by National Collaborating Centre for Chronic Conditions (Great Britain) and published by Royal College of Physicians. This book was released on 2006 with total page 243 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Non Motor Symptoms of Parkinson s Disease written by K. Ray Chaudhuri and published by Oxford University Press, USA. This book was released on 2014 with total page 517 pages. Available in PDF, EPUB and Kindle. Book excerpt: Patients with Parkinson's disease (PD) are known to suffer from motor symptoms of the disease, but they also experience non-motor symptoms (NMS) that are often present before diagnosis or that inevitably emerge with disease progression. The motor symptoms of Parkinson's disease have been extensively researched, and effective clinical tools for their assessment and treatment have been developed and are readily available. In contrast, researchers have only recently begun to focus on the NMS of Parkinson's Disease, which are poorly recognized and inadequately treated by clinicians. The NMS of PD have a significant impact on patient quality of life and mortality and include neuropsychiatric, sleep-related, autonomic, gastrointestinal, and sensory symptoms. While some NMS can be improved with currently available treatments, others may be more refractory and will require research into novel (non-dopaminergic) drug therapies for the future. Edited by members of the UK Parkinson's Disease Non-Motor Group (PD-NMG) and with contributions from international experts, this new edition summarizes the current understanding of NMS symptoms in Parkinson's disease and points the way towards future research.
Download or read book Therapeutics of Parkinson s Disease and Other Movement Disorders written by Mark Hallett and published by John Wiley & Sons. This book was released on 2008-10-13 with total page 520 pages. Available in PDF, EPUB and Kindle. Book excerpt: Provides a comprehensive update on therapies for Parkinson’s disease and other movement disorders Describes the basic mechanisms of neurodegeneration, pharmacologic interventions for motor and non-motor symptoms, and surgical management Features summary tables and algorithms that serve as a quick reference guide for practical treatment decisions The expert guidance of recognised authorities will enable readers of this book to plan their patients’ care with greater confidence
Download or read book Ending Parkinson s Disease written by Ray Dorsey and published by PublicAffairs. This book was released on 2020-03-17 with total page 271 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this "must-read" guide (Lonnie Ali), four leading doctors and advocates offer a bold action plan to prevent, care for, and treat Parkinson's disease-one of the great health challenges of our time. Brain diseases are now the world's leading source of disability. The fastest growing of these is Parkinson's: the number of impacted patients has doubled to more than six million over the last twenty-five years and is projected to double again by 2040. Harmful pesticides that increase the risk of Parkinson's continue to proliferate, many people remain undiagnosed and untreated, research funding stagnates, and the most effective treatment is now a half century old. In Ending Parkinson's Disease, four top experts provide a plan to help prevent Parkinson's, improve care and treatment, and end the silence associated with this devastating disease.
Download or read book Recent Advances in Parkinsons Disease written by and published by Elsevier. This book was released on 2010-10-13 with total page 369 pages. Available in PDF, EPUB and Kindle. Book excerpt: This second volume follows on from Part I by reviewing the variety of animal models of PD current available (from drosophila to rodents to non-human primate species) and their specific contributions to PD research. This is followed by comprehensive coverage of functional neuroimaging studies that explore different pathophysiological questions and evaluate treatment outcome in PD patients. Different areas of experimental therapeutics and outstanding challenges to PD treatment are presented in a concluding group of articles. Complete overview of hot topics and approaches to current PD research, from molecules, to brain circuits, to clinical and therapeutic applications Leading authors review the state-of-the-art in their field of investigation, and provide their views and perspectives for future research All chapters include comprehensive background information and are written in a clear form that is also accessible to the non-specialist
Download or read book An Essay on the Shaking Palsy written by James Parkinson and published by . This book was released on 1817 with total page 86 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Neurorehabilitation in Parkinson s Disease written by Marilyn Trail and published by SLACK Incorporated. This book was released on 2008 with total page 384 pages. Available in PDF, EPUB and Kindle. Book excerpt: 'Neurorehabilitation in Parkinson's Disease' serves as a reference for the treatment of patients with Parkinson's disease. In addition to providing treatment models for physical therapy, occupational therapy, & speech-language pathology, the text covers topics such as review of pathophysiology, & symptomatology.
